Developer docs
API playgroundTry for free, no card

Search company profiles

Tiziana Life Sciences

Full company profile

uuid0003a1e

Namestring
Tiziana Life Sciences
Legal namestring
Tiziana Life Sciences plc
Company typeenum
Public
Founded yearint
2013
Descriptiontext

Tiziana Life Sciences plc (NASDAQ: TLSA) is a clinical-stage biotechnology company developing intranasal immunomodulation therapies for neuroinflammatory and neurodegenerative diseases, incorporated in Bermuda with operational offices in Boston and London. The company's lead and only clinically advanced asset is intranasal foralumab (TZLS-401), the only fully human anti-CD3 monoclonal antibody in clinical development, which it positions as a non-invasive alternative to intravenous anti-CD3 delivery, stimulating T regulatory cells to dampen microglial activation and reduce neuroinflammation. The pipeline is anchored by Phase 2 programs in non-active Secondary Progressive Multiple Sclerosis (48-patient INFORM-MS trial with enrollment completed May 2026), Multiple System Atrophy (Phase 2a TILS-025 trial), and mild-to-moderate Alzheimer's Disease, supplemented by Expanded Access Programs, an ALS program accepted into the Healey MyMatch Program, and preclinical work in Long COVID and intracerebral hemorrhage.

The company generates no commercial revenue and operates as a research-driven biotech, conducting multicenter trials through partnerships with Brigham and Women's Hospital and Mass General Brigham under the scientific leadership of Dr. Howard Weiner, and drawing on NIH and ALS Association grant funding alongside periodic registered direct equity offerings. Insider ownership is concentrated, with Executive Chairman Gabriele Cerrone holding approximately 34.89% of issued shares and CEO Ivor Elrifi materially participating in recent raises. Patent protection on the foralumab composition, formulation, and indication space extends to 2040. Revenue mechanics are pre-commercial: future value creation depends on Phase 2/3 readouts (MS topline expected late Q3/early Q4 2026), potential licensing deals, and the planned spin-out of the second asset TZLS-501 (anti-IL-6 receptor mAb) into a separate publicly traded entity.

Short descriptiontext

Tiziana Life Sciences is a clinical-stage biotechnology company developing intranasal foralumab, the only fully human anti-CD3 monoclonal antibody in clinical development, for neuroinflammatory and neurodegenerative diseases including MS, Alzheimer's, MSA, and ALS.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
intranasal immunotherapy, monoclonal antibody therapy, neuroinflammatory disease treatment, biopharmaceutical drug development, clinical stage biotechnology
Industry4 codes
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Clinical-stage Biopharmaceuticals (Neuroimmunology)
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Biopharmaceutical Development
TypeOne Time License
Description

Pre-revenue clinical-stage biopharmaceutical company. Developing breakthrough therapies for neuroinflammatory and neurodegenerative diseases. No commercial products yet - all candidates are in clinical development stages.

investing.com
2Potential Future Licensing/Spinout - TZLS-501
TypeLicensing Royalties
Description

Company announced plans to spin out its anti-IL-6 receptor monoclonal antibody TZLS-501 into a separate publicly traded company, citing increased industry interest exemplified by Novartis' recent acquisition of Tourmaline Bio. This represents potential future licensing or spinout revenue stream.

fiercebiotech.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing intranasal foralumab (TZLS-401), the only fully human anti-CD3 monoclonal antibody in clinical development, for neuroinflammatory and neurodegenerative diseases including non-active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's Disease, and ALS. The company also develops an anti-IL-6 receptor monoclonal antibody (TZLS-501) for lung diseases and is exploring milciclib in oncology.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 83% of patients (5 of 6) showed reduction in microglial PET signal after 3 and 6 months of treatment
+4 more records
Product and service3 records
1Intranasal Foralumab (TZLS-401)
CategoryBiologic Drug Candidate — Anti-CD3 Monoclonal Antibody
Description

Intranasal Foralumab (TZLS-401) is the only fully human anti-CD3 monoclonal antibody in clinical development, delivered via Tiziana's proprietary intranasal platform to stimulate T regulatory cells and reduce neuroinflammation. It is being developed for non-active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's Disease, ALS, Long COVID, and other neuroinflammatory indications. Patents covering composition, formulation, and indications are protected through 2040.

2Anti-IL-6 Receptor Monoclonal Antibody (TZLS-501)
CategoryBiologic Drug Candidate — Anti-IL-6R Monoclonal Antibody
Description

Anti-IL-6 Receptor Monoclonal Antibody (TZLS-501) is a fully human monoclonal antibody targeting the receptor for IL-6, being developed as a potential treatment for lung diseases and being positioned for spinout into a separate publicly traded company.

3Milciclib
CategorySmall Molecule Oncology Candidate
Description

Milciclib is being explored by Tiziana in a combination study with gemcitabine in NSCLC subjects with associated pan-KRAS-positive mutations.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2026-04-16
Description

Collaborated with Yale University researchers on preclinical data for Long COVID study. Research demonstrated that intranasal foralumab reduced neuroinflammation and improved cognitive function in mouse model of Long COVID.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-25
Description

Primary research partner conducting multiple clinical trials including Phase 2a na-SPMS trial (INFORM-MS), Phase 2 MSA trial (TILS-025), and Expanded Access Programs for Alzheimer's disease. Led by Dr. Howard Weiner and Dr. Tanuja Chitnis. Founded by researchers with decades of experience in neuroinflammatory diseases.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-25
Description

Major healthcare system overseeing clinical trial sites. Phase 2 ALS trial accepted into Healey ALS MyMatch Program at Mass General Brigham. Multiple hospitals within network serve as clinical trial sites.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Small-cap clinical-stage biotech focused on neurodegenerative diseases including Alzheimer's and Rett syndrome. Directly comparable to Tiziana in size, stage, indication overlap, and pre-revenue clinical development model.

TypeDirect peer
Description

Clinical-stage biotech developing neuroinflammation and immunology therapies. Comparable in immunomodulation mechanism, small-cap clinical structure, and CNS indication focus.

TypeDirect peer
Description

Clinical-stage biotech developing monoclonal antibody therapies for neurodegenerative diseases including Parkinson's and Alzheimer's. Comparable in biologics platform, neuro focus, and pipeline-driven small-cap profile.

TypeDirect peer
Description

CNS-focused biotech developing therapies for neurological disorders including multiple sclerosis. Comparable in neuro-focused pipeline, monoclonal antibody/biologics development, and small-cap clinical-stage structure.

TypeDirect peer
Description

Clinical-stage biotech developing gene therapy and antibody therapeutics for neurological diseases including Alzheimer's and ALS. Comparable in CNS indication focus and clinical-stage development model.

6Cassava Sciences
TypeDirect peer
Description

Clinical-stage biotech developing simufilam for Alzheimer's disease. Closely comparable in market cap, single-asset narrative, Phase 2/3 readout catalysts, and small-cap neurodegenerative focus.

TypeDirect peer
Description

Clinical-stage biotech developing therapeutics for neurodegenerative diseases including Parkinson's, Alzheimer's, and ALS. Comparable in neuroimmunology pipeline, biologics approach, and multi-indication strategy.

TypeDirect peer
Description

Clinical-stage biotech developing therapeutics and diagnostics for neurodegenerative diseases. Comparable in anti-amyloid and neuroinflammation focus, biologics platform, and partnership-driven clinical development model.

TypeDirect peer
Description

Clinical-stage biotech developing T-cell and monoclonal antibody immunotherapies. Comparable in biologics platform, immunomodulation mechanism, and MS/neuro indications.

TypeDirect peer
Description

Clinical-stage biotech developing complement-mediated neuroinflammation therapeutics for neurodegenerative diseases. Directly comparable in neuroinflammatory mechanism, Phase 2 stage, and indication overlap (MS, ALS, Alzheimer's).

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Tiziana Life Sciences

Clinical-stage Biopharmaceuticals (Neuroimmunology)tizianalifesciences.com

Tiziana Life Sciences is a clinical-stage biotechnology company developing intranasal foralumab, the only fully human anti-CD3 monoclonal antibody in clinical development, for neuroinflammatory and neurodegenerative diseases including MS, Alzheimer's, MSA, and ALS.

What Tiziana Life Sciences does

Tiziana Life Sciences plc (NASDAQ: TLSA) is a clinical-stage biotechnology company developing intranasal immunomodulation therapies for neuroinflammatory and neurodegenerative diseases, incorporated in Bermuda with operational offices in Boston and London. The company's lead and only clinically advanced asset is intranasal foralumab (TZLS-401), the only fully human anti-CD3 monoclonal antibody in clinical development, which it positions as a non-invasive alternative to intravenous anti-CD3 delivery, stimulating T regulatory cells to dampen microglial activation and reduce neuroinflammation. The pipeline is anchored by Phase 2 programs in non-active Secondary Progressive Multiple Sclerosis (48-patient INFORM-MS trial with enrollment completed May 2026), Multiple System Atrophy (Phase 2a TILS-025 trial), and mild-to-moderate Alzheimer's Disease, supplemented by Expanded Access Programs, an ALS program accepted into the Healey MyMatch Program, and preclinical work in Long COVID and intracerebral hemorrhage.

The company generates no commercial revenue and operates as a research-driven biotech, conducting multicenter trials through partnerships with Brigham and Women's Hospital and Mass General Brigham under the scientific leadership of Dr. Howard Weiner, and drawing on NIH and ALS Association grant funding alongside periodic registered direct equity offerings. Insider ownership is concentrated, with Executive Chairman Gabriele Cerrone holding approximately 34.89% of issued shares and CEO Ivor Elrifi materially participating in recent raises. Patent protection on the foralumab composition, formulation, and indication space extends to 2040. Revenue mechanics are pre-commercial: future value creation depends on Phase 2/3 readouts (MS topline expected late Q3/early Q4 2026), potential licensing deals, and the planned spin-out of the second asset TZLS-501 (anti-IL-6 receptor mAb) into a separate publicly traded entity.

Tiziana Life Sciences firmographics

Firmographics
Name
Tiziana Life Sciences
Legal name
Tiziana Life Sciences plc
Website
https://tizianalifesciences.com
Company type
Public
Founded year
2013
Operating status
Operating
Headcount range
1–10 employees
Short description
Tiziana Life Sciences is a clinical-stage biotechnology company developing intranasal foralumab, the only fully human anti-CD3 monoclonal antibody in clinical development, for neuroinflammatory and neurodegenerative diseases including MS, Alzheimer's, MSA, and ALS.
Ownership category
akta.pro rank

Tiziana Life Sciences industry classification

Industry
Product category
Clinical-stage Biopharmaceuticals (Neuroimmunology)
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Intranasal immunotherapy
  • Monoclonal antibody therapy
  • Neuroinflammatory disease treatment
  • Biopharmaceutical drug development
  • Clinical stage biotechnology

Where Tiziana Life Sciences is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices3 records

Markets served

Tiziana Life Sciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Biopharmaceutical Development: Pre-revenue clinical-stage biopharmaceutical company. Developing breakthrough therapies for neuroinflammatory and neurodegenerative diseases. No commercial products yet - all candidates are in clinical development stages.
  2. Potential Future Licensing/Spinout - TZLS-501: Company announced plans to spin out its anti-IL-6 receptor monoclonal antibody TZLS-501 into a separate publicly traded company, citing increased industry interest exemplified by Novartis' recent acquisition of Tourmaline Bio. This represents potential future licensing or spinout revenue stream.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Tiziana Life Sciences product offering

Product offering

Core offering

Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing intranasal foralumab (TZLS-401), the only fully human anti-CD3 monoclonal antibody in clinical development, for neuroinflammatory and neurodegenerative diseases including non-active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's Disease, and ALS. The company also develops an anti-IL-6 receptor monoclonal antibody (TZLS-501) for lung diseases and is exploring milciclib in oncology.

Differentiator

Problem solved

Functional benefit

Products and services

  • Intranasal Foralumab (TZLS-401) Intranasal Foralumab (TZLS-401) is the only fully human anti-CD3 monoclonal antibody in clinical development, delivered via Tiziana's proprietary intranasal platform to stimulate T regulatory cells and reduce neuroinflammation. It is being developed for non-active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's Disease, ALS, Long COVID, and other neuroinflammatory indications. Patents covering composition, formulation, and indications are protected through 2040.
  • Anti-IL-6 Receptor Monoclonal Antibody (TZLS-501) Anti-IL-6 Receptor Monoclonal Antibody (TZLS-501) is a fully human monoclonal antibody targeting the receptor for IL-6, being developed as a potential treatment for lung diseases and being positioned for spinout into a separate publicly traded company.
  • Milciclib Milciclib is being explored by Tiziana in a combination study with gemcitabine in NSCLC subjects with associated pan-KRAS-positive mutations.

Quantifiable outcome

  • 83% of patients (5 of 6) showed reduction in microglial PET signal after 3 and 6 months of treatment
  • +4 more outcomes

Companies that use Tiziana Life Sciences

Customer profile

Named customers3 records

Segments2 records

Ideal customer profiles3 records

Tiziana Life Sciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Tiziana Life Sciences partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered supporting and core.

  • Yale UniversitysupportingStrategic or Co-development Partner · 16 April 2026Collaborated with Yale University researchers on preclinical data for Long COVID study. Research demonstrated that intranasal foralumab reduced neuroinflammation and improved cognitive function in mouse model of Long COVID.
  • Brigham and Women's HospitalcoreStrategic or Co-development Partner · 25 November 2025Primary research partner conducting multiple clinical trials including Phase 2a na-SPMS trial (INFORM-MS), Phase 2 MSA trial (TILS-025), and Expanded Access Programs for Alzheimer's disease. Led by Dr. Howard Weiner and Dr. Tanuja Chitnis. Founded by researchers with decades of experience in neuroinflammatory diseases.
  • Mass General BrighamcoreStrategic or Co-development Partner · 25 November 2025Major healthcare system overseeing clinical trial sites. Phase 2 ALS trial accepted into Healey ALS MyMatch Program at Mass General Brigham. Multiple hospitals within network serve as clinical trial sites.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Tiziana Life Sciences competitors and assessment

Company assessment

Direct peers

  • Anavex Life Sciences: Small-cap clinical-stage biotech focused on neurodegenerative diseases including Alzheimer's and Rett syndrome. Directly comparable to Tiziana in size, stage, indication overlap, and pre-revenue clinical development model.
  • BioXcel Therapeutics: Clinical-stage biotech developing neuroinflammation and immunology therapies. Comparable in immunomodulation mechanism, small-cap clinical structure, and CNS indication focus.
  • Prothena Corporation: Clinical-stage biotech developing monoclonal antibody therapies for neurodegenerative diseases including Parkinson's and Alzheimer's. Comparable in biologics platform, neuro focus, and pipeline-driven small-cap profile.
  • Sage Therapeutics: CNS-focused biotech developing therapies for neurological disorders including multiple sclerosis. Comparable in neuro-focused pipeline, monoclonal antibody/biologics development, and small-cap clinical-stage structure.
  • Voyager Therapeutics: Clinical-stage biotech developing gene therapy and antibody therapeutics for neurological diseases including Alzheimer's and ALS. Comparable in CNS indication focus and clinical-stage development model.
  • Cassava Sciences: Clinical-stage biotech developing simufilam for Alzheimer's disease. Closely comparable in market cap, single-asset narrative, Phase 2/3 readout catalysts, and small-cap neurodegenerative focus.
  • Denali Therapeutics: Clinical-stage biotech developing therapeutics for neurodegenerative diseases including Parkinson's, Alzheimer's, and ALS. Comparable in neuroimmunology pipeline, biologics approach, and multi-indication strategy.
  • AC Immune SA: Clinical-stage biotech developing therapeutics and diagnostics for neurodegenerative diseases. Comparable in anti-amyloid and neuroinflammation focus, biologics platform, and partnership-driven clinical development model.
  • Atara Biotherapeutics: Clinical-stage biotech developing T-cell and monoclonal antibody immunotherapies. Comparable in biologics platform, immunomodulation mechanism, and MS/neuro indications.
  • Annexon, Inc. Clinical-stage biotech developing complement-mediated neuroinflammation therapeutics for neurodegenerative diseases. Directly comparable in neuroinflammatory mechanism, Phase 2 stage, and indication overlap (MS, ALS, Alzheimer's).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

Tiziana Life Sciences social profiles

Digital presence

Tiziana Life Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Tiziana Life Sciences leadership team

Management profile

Number of profiles

Profiles5 records

Tiziana Life Sciences funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Tiziana Life Sciences M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tiziana Life Sciences

What does Tiziana Life Sciences do?

Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing intranasal foralumab (TZLS-401), the only fully human anti-CD3 monoclonal antibody in clinical development, for neuroinflammatory and neurodegenerative diseases including non-active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's Disease, and ALS. The company also develops an anti-IL-6 receptor monoclonal antibody (TZLS-501) for lung diseases and is exploring milciclib in oncology.

Is Tiziana Life Sciences a public or private company?

Tiziana Life Sciences is a public company. It is classified as public and is currently operating.

When was Tiziana Life Sciences founded?

Tiziana Life Sciences was founded in 2013. It employs 1 to 10 people.

Where is Tiziana Life Sciences based?

Tiziana Life Sciences is headquartered in London, United Kingdom, in the Europe region.

How does Tiziana Life Sciences make money?

Two revenue lines are on record. Biopharmaceutical Development is the primary driver. The others are potential Future Licensing/Spinout - TZLS-501.

Who are Tiziana Life Sciences's main competitors?

Direct peers on record are Anavex Life Sciences, BioXcel Therapeutics, Prothena Corporation, Sage Therapeutics, Voyager Therapeutics, Cassava Sciences, Denali Therapeutics, AC Immune SA, Atara Biotherapeutics and Annexon, Inc..

Does Tiziana Life Sciences have an API?

No public API is recorded for Tiziana Life Sciences.

What industry is Tiziana Life Sciences in?

Tiziana Life Sciences's product category is Clinical-stage Biopharmaceuticals (Neuroimmunology). Its primary akta.pro industry code is HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs), with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialTiziana Life Sciences To Present At The Jefferies Global Healthcare Conference 2026 In LondonTiziana Life Sciences will present at the Jefferies Global Healthcare Conference in London on November 18, 2026, covering its Phase 2a INFORM-MS trial results for intranasal foralumab in non-active secondary progressive multiple sclerosis. The trial met dual primary endpoints, including a statistically significant reduction in microglial activation and favorable safety. The company will also discuss the KOL call held on November 9, 2026.The future of tradingTiziana Life Sciences Publishes Presentation on INFORM-MS Phase 2 Trial ResultsTiziana Life Sciences published its INFORM-MS Phase 2 trial results, showing intranasal foralumab met both primary endpoints in non-active secondary progressive MS. The 50-microgram dose significantly reduced neuroinflammation versus placebo at 12 weeks (p=0.0168), and fatigue scores improved by 6.17 points. No serious adverse events occurred, and all 48 participants completed treatment.Business & FinancialTiziana Life Sciences To Present At BIO-Europe 2026 And Host KOL WebcastTiziana Life Sciences CEO Ivor Elrifi will present at BIO-Europe on November 10, 2026, and host a KOL webcast on November 9, 2026, to discuss positive Phase 2a INFORM-MS topline results for intranasal foralumab in non-active secondary progressive multiple sclerosis. The company will also engage with partners on its pipeline for Alzheimer's, MSA, and ALS.Stock TitanTiziana to present at BIO-Europe, host trial-results webcastTiziana Life Sciences will present at BIO-Europe 2026 and host a KOL webcast on November 9, 2026, to discuss positive topline results from the Phase 2a INFORM-MS trial of intranasal foralumab in non-active secondary progressive multiple sclerosis. The company will also engage with partners to discuss potential collaborations.TradingViewTiziana Life Sciences (TLSA) Reports Phase 2a MS Trial ResultsTiziana Life Sciences reported that its Phase 2a INFORM-MS trial met dual primary endpoints, including reduced microglial activation on TSPO PET and statistically significant fatigue improvements. Fatigue scores fell 6.17 points in the 50 μg arm and 7.18 points in the 100 μg arm, with all 48 participants completing 12 weeks. The company plans FDA discussions on next steps.YahooTiziana’s Phase IIa trial of foralumab meets dual endpoints in na-SPMSTiziana Life Sciences reported that its Phase IIa INFORM-MS trial of intranasal foralumab met dual primary endpoints in non-active secondary progressive multiple sclerosis. The 50μg and 100μg doses significantly reduced neuroinflammation and were safe, with no serious adverse events. The trial enrolled 48 patients across eight US centres.NasdaqTiziana's Intranasal Foralumab Meets Primary Endpoints In Phase 2a Multiple Sclerosis TrialTiziana Life Sciences reported positive topline results from its Phase 2a INFORM-MS trial, where intranasal foralumab met both primary endpoints in non-active secondary progressive MS patients. The 50-microgram dose reduced microglial activation, and both doses were safe, with fatigue scores improving by 6.17 and 7.18 points. The company plans to complete analysis and discuss next steps with the FDA.Nate티지아나, 비강형 다발성경화증 치료제 2상서 주요 목표 충족 : 네이트 뉴스Tiziana Life Sciences reported that its nasal foralumab met primary endpoints in the INFORM-MS Phase 2a trial for non-active secondary progressive multiple sclerosis. The 48-patient study showed reduced brain inflammation and a favorable safety profile. The company plans an open-label extension to assess long-term effects.Seeking AlphaTiziana falters following mid-stage results for multiple sclerosis assetTiziana Life Sciences fell about 13% on Monday after reporting phase 2a results for intranasal foralumab in non-active secondary progressive multiple sclerosis. The results met dual primary endpoints, including a statistically significant reduction in neuroinflammation after 12 weeks.TradingViewTiziana falters following mid-stage results for multiple sclerosis assetTiziana Life Sciences fell about 13% on Monday after reporting phase 2a results for its intranasal foralumab in non-active secondary progressive multiple sclerosis. The 50 μg dose showed a statistically significant reduction in neuroinflammation, but the 100 μg dose did not, and the stock decline may reflect that.